Member LoginDividend CushionValue Trap |
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Mar 26, 2012
Framing Our Thoughts on the "Earnings Game" and the Equity Markets
We outline our thoughts on the "earnings game" and the equity markets. A helpful read for the beginner or even the experienced investor. Mar 23, 2012
FedEx Posts Strong Fiscal Third-Quarter Results, But Outlook Disappoints
FedEx reported strong fiscal third-quarter results, but its outlook left something to be desired. We don't expect to change our fair value estimate for FedEx, but we'll be digging deeper into our views on the global economy during 2012. Mar 6, 2012
Qualcomm Hikes Dividend, Announces Share Buyback Program
Qualcomm announced that it would raise its dividend 16%, slightly higher than what we were expecting, and implemented a $4 billion share repurchase program. Though we were pleased with the developments, our fair value estimate for the company remains unchanged. Feb 29, 2012
First Solar Misses Yet Again; We Expect Further Valuation Downside
First Solar reported disappointing fourth-quarter results, and a few events in the quarter suggest to us the worst of times still lie ahead for the company. We'd steer clear of the firm's shares. Feb 21, 2012
Kraft's Pricing Power Is Unmatched By Peers in Fourth Quarter; Waiting Patiently for the Break Up
Kraft posted solid fourth-quarter results that showed tremendous pricing power, which offset declines in volume. Though we liked the quarter, we remain on the sidelines with respect to Kraft's shares until after the company separates the firm into two entities later this year: a global-snacks company and a North American grocery products firm. Feb 7, 2012
Coca-Cola Posts Fourth-Quarter Results; Focus Remains on Controlling Costs
Coca-Cola reported strong fourth-quarter results that revealed impressive international expansion. Though we like the firm's growth prospects and cost-cutting initiatives, the shares remain fairly valued. Feb 3, 2012
Gilead Sciences Releases Favorable Hepatitus C Data
Gilead Sciences reported fourth-quarter results and released favorable hepatitus C data for its all-oral regimen to treat the virus, and the shares are rallying nearly 10% on the promising news. The firm has now converged to our $54 per share fair value estimate. Feb 1, 2012
Valuentum's February Edition of its Dividend Growth Newsletter!
The February edition of our Dividend Growth Newsletter is now available. Jan 27, 2012
Best-Idea Ford Hits Profit Snag in Fourth Quarter; 2012 Pre-Tax Operating Profit to Hold Flat
Best-idea Ford showed strong revenue performance but weak underlying profitability in its fourth-quarter results. We view the automaker as a long-term holding in the portfolio of our Best Ideas Newsletter and expect ongoing improvement from the company in the years ahead. Jan 27, 2012
Starbucks is Firing on All Cylinders But Shares Are Expensive
Starbucks put up record fiscal first-quarter results for both revenue and earnings. Though we like the coffee giant's future potential opportunities, its shares are rich at present levels.
prev12345678910111213141516171819202122232425
26272829303132333435363738394041424344454647484950 51525354555657585960616263646566676869707172737475 767778798081828384858687888990919293949596979899100 101102103104105106107108109110111112113114115116117118119120 121122123124125126127128129130131132133134135136137138139140 141142143144145146147148149150151152153154155156157158159160 161162163164165166167168169170171172173174175176177178179180 181182183184185186187188189190191192193194195196197198199200 next The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|